Fjarde AP Fonden Fourth Swedish National Pension Fund Decreases Stake in IQVIA Holdings Inc. (NYSE:IQV)

Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 16.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 35,456 shares of the medical research company’s stock after selling 6,900 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in IQVIA were worth $6,967,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new position in IQVIA in the 3rd quarter valued at about $27,000. Synergy Asset Management LLC purchased a new position in IQVIA in the 4th quarter valued at about $33,000. Avior Wealth Management LLC boosted its position in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the last quarter. Assetmark Inc. boosted its position in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares during the last quarter. Finally, Concord Wealth Partners bought a new position in shares of IQVIA during the third quarter worth about $57,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at IQVIA

In related news, Director John G. Danhakl acquired 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were acquired at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

Shares of NYSE:IQV opened at $194.71 on Tuesday. The firm’s 50 day moving average is $199.52 and its two-hundred day moving average is $215.96. IQVIA Holdings Inc. has a 52 week low of $187.62 and a 52 week high of $261.73. The firm has a market capitalization of $34.29 billion, a P/E ratio of 25.96, a PEG ratio of 1.99 and a beta of 1.48. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. The Goldman Sachs Group reduced their price target on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Deutsche Bank Aktiengesellschaft reduced their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. UBS Group reduced their price target on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Stephens initiated coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and an average price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.